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Secreted frizzled-related protein-1 (SFRP1) is a negative regulatory molecule of the
WNT signaling pathway and serves as a therapeutic target for bone formation in
osteoporosis. In this study, we first established an ovariectomized (OVX) rat model to
simulate postmenopausal osteoporosis and found significant changes in miR-542-3p
and sFRP1 expression by RNA sequencing and qRT-PCR. In addition, there was a
significant negative correlation between miR-542-3p and sFRP1 mRNA levels in
postmenopausal women with osteoporosis. We found that miR-542-3p inhibited the
expression of sFRP1 mRNA by luciferase reporter assay. When the miR-542-3p
binding site in sFRP1 3'UTR was deleted, it did not affect its expression. Western blot
results showed that miR-542-3p inhibited the expression of SFRP1 protein. The
expression of SFRP1 was significantly increased in osteoblast-induced mesenchymal
stem cells (MSC), whereas the expression of miR-542-3p was significantly decreased.
And miR-542-3p transfected MSCs showed a significant increase in osteoblast-
specific marker expression, indicating that miR-542-3p is necessary for MSC
differentiation. Inhibition of miR-542-3p reduced bone formation, confirmed miR-
542-3p play a role in bone formation in vivo. In general, these data suggest that miR-
542-3p play an important role in bone formation via inhibiting SFRP1 expression and
inducing osteoblast differentiation.
K E YWORD S
differentiation, miRNA, osteoporosis, SFRP1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2018 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.
Xiguang Zhang and Yun Zhu contributed equally to this work.
6798 | wileyonlinelibrary.com/journal/jcp J Cell Physiol. 2018;233:6798–6806.
1 | INTRODUCTION
Osteoporosis is a bone metabolic disease characterized by a decrease
in bone mass and bone mineral density (BMD), and a degradation of
bone tissue microstructures, which lead to an increase in bone fragility
and fracture incidence (Kanis et al., 2013; Roux & Briot, 2017). The
main pathogenesis of osteoporosis is caused by bone remodeling
disorders, which are due to osteoclast-mediated bone resorption rates
higher than osteoblast-mediated bone formation (Bidwell, Alvarez, &
Childress, 2013). The incidence of osteoporosis in the elder population
is higher (senile osteoporosis) (Li et al., 2017). In particular,
postmenopausal women (postmenopausal osteoporosis) are prone
to osteoporosis because of estrogen deficiency is associated with
excessive bone resorption and poor bone formation (Epstein, 2006;
Heiss et al., 2012). However, the detailed mechanisms of estrogen
deficiency in postmenopausal osteoporosis have not been fully
understood.
The canonical Wnt/β-catenin signaling pathway plays a vital role
in activating bone formation and resorption genes transcription, and
then regulate osteoblast differentiation, proliferation, survival, and
bone formation (Zhang & Drake, 2012). SFRP1 is homologous to the
extracellular cysteine-rich domain of the WNT receptor Frizzled, but
lacks the intracellular and transmembrane domains (Yang et al., 2009).
It has been reported that competition with extracellular Wnt binds to
the Frizzled receptors, and further antagonizesWnt signaling by direct
binding to Wnt proteins (Gaur et al., 2006; Hausler et al., 2004).
Previous studies have shown that SFRP1 plays an important role in
osteoblast differentiation, trabecular bone formation and bone
fracture healing (Bodine et al., 2004; Bodine, Seestaller-Wehr,
Kharode, Bex, & Komm, 2007; Gaur et al., 2006, 2009). Thus, the
development of inhibitors against SFRP1 is a viable method of
stimulating bone formation in metabolic bone diseases, osteoporosis
and aging (Baron & Rawadi, 2007; Gaur et al., 2009).
MicroRNAs (miRNAs) is a class of small non-coding (18–25
nucleotides) single-stranded RNAs that binds to an incomplete or
complete base pairing of a specific sequence in the 3′ untranslated
regions (3′UTRs) or CDS of mRNAs, then induces either translational
repression or cleavage of the target mRNAs (Noma et al., 2004;
Schramke & Allshire, 2003). MiRNAs play important roles in a variety of
biological processes, such as cell proliferation, differentiation, apoptosis,
and tumorigenesis (Yang et al., 2013; Yin et al., 2013; Zhang,Wei, & Xu,
2013). Recently, numerous studies have revealed that miRNAs play
critical roles in bone homeostasis. For example, miR-433-3p plays an
critical role in DKK1/WNT/beta-catenin pathway by reducing DKK1
expression and inducing osteoblast differentiation (Tang, Lin, Wang, &
Lu, 2017). MiR-23a cluster regulates osteoblast differentiation by
attenuating Prdm16 expression level to modulate the TGF-β signaling
pathway (Zeng et al., 2017). However, the role of miRNAs in the
pathogenesis of osteoporosis remains to be further studied.
In this study,we found that sFRP1andmiR-542-3pwere negatively
correlated in postmenopausal osteoporosis patients. Then, miRNA
target analysis andexperiments showed that sFRP1was a target ofmiR-
542-3p. Further studies have shown that miR-542-3p plays a vital role
during the process of MSC differentiation. In general, our study show
that miR-542-3p play an important role in bone formation by targeting
SFRP1 and inducing osteoblasts differentiation.
2 | RESULTS
2.1 | MiR-542-3p is differentially expressed and
negatively correlated with SFRP1 in postmenopausal
osteoporotic patients
We chose estrogen deficient ovariectomized (OVX) rats model to
mimic postmenopausal osteoporosis, because it is close to postmeno-
pausal bone loss (Kalu, 1991). A total of 45 or 90 days after surgery, the
bone mineral density (BMD) of right femoral in OVX rats was lower
than that in sham operation group (Sham) (p < 0.05) (Table 1).
Compared with sham rats, OVX rats also showed increased trabecular
separation (Figure 1). It indicated that ovariectomy-induced osteopo-
rosis in rat model has been established.
To compare themRNAs expression profiles in theMSCs fromOVX
rats and Sham rats, three subjects of each subgroup were selected for
RNA-seq assays. mRNAs with log2(fold change) >3-fold were
determined as putative candidates. As shown in Table 2, six mRNAs
were up-regulated and 22 mRNAs were down-regulated. In the
dramatically up-regulated mRNAs, SFRP1 is an antagonist of Wnt
signaling and play an important role in maintaining bone homeostasis
(Baron & Rawadi, 2007; Gaur et al., 2009). So we selected sFRP1 as a
candidate gene. The expression of SFRP1 was detected in three
subjects using western blot and qRT-PCR assay, and the results were
consistentwith RNA-seq expression (Figures 2a and b).Meanwhile, we
compared the expression of microRNAs in the MSCs from OVX rats
and Sham rats (Supplementary Table SI). Among microRNAs that
contain the binding sites of sFRP1 (Supplementary Table SII), the
expression of miR-542-3p is significantly downregulated in the OVX
group (Figure 2c). Finally, the relationship between miR-542-3p and
sFRP1 expression levels in postmenopausal osteoporotic patients was
analyzed and plotted on the graph shown in Figure 2d. Correlation
analysis showed a significant negative correlation between sFRP1 and
miR-542-3p expression (Figure 2d).
2.2 | MiR-542-3p directly targets sFRP1
It has been demonstrated that miRNAs regulate the mRNA expression
of by binding to the 3′-UTR or amino acid coding sequence (CDS) of
target gene (Tay, Zhang, Thomson, Lim, & Rigoutsos, 2008). Based on
TABLE 1 Bone mineral density of the femur
0 d (mg/cm2) 45 d (mg/cm2) 90 d (mg/cm2)
Sham 182.44 ± 19.24 175.17 ± 15.15 168.06 ± 17.67
OVX 186.88 ± 20.45 140.70 ± 18.93 126.32 ± 14.90
p value >0.05 <0.05 <0.05
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the bioinformatics online analysis software (TargetScan), miR-542-3p
was predicted to target in the 3′UTR of sFRP1.
To investigatewhethermiR-542-3p is directly targeted to SFRP1,we
firstly constructed luciferase reporter vectors which contained the
predicted miRNA binding site of sFRP1 3'UTR or deleted mutant
(Figure 3a). Then we introduced the luciferase expression vector
containing the 3′UTR of sFRP1 (pGL3-sFRP1-3′UTR-WT) and miR-
542-3p into HEK293T cells, andmeasured the level of luciferase enzyme
activity, which reflected the effects of miR-542-3p on luciferase
translation. The results showed that overexpression of miR-542-3p
suppressed the luciferase activity of the sFRP1 3′UTR reporter gene
(Figure 3b). The deletion of the 9 nt continuous site complementary to
miR-542-3p in the 3′UTR of sFRP1 (pGL3-sFRP1-3′UTR-Mut) eliminates
this inhibition, which confirmed the specificity of this action (Figure 3b).
In order to identify the effect of miR-542-3p on sFRP1 expression,
miR-542-3p was transfected into HEK293T cells and the protein level
of SFRP1 was measured by western blot. Overexpression of miR-542-
3p significantly inhibited the protein level of endogenous SFRP1
compared to the control (Figure 3c).
These results indicate that sFRP1 is the target gene formiR-542-3p.
2.3 | MiR-542-3p increased osteogenic
differentiation
Wefirst isolated theMSCfromthe rats andthen induced todifferentiate
into osteoblasts. The expression of miR-542-3p and sFRP1 was
measured from 1 to 3 weeks after induction. Osteoblast-induced cells
showed a significant increase in the expression level of sFRP1 from 1 to
3weeks (Figure 4a). In contrast, the expression level ofmiR-542-3pwas
significantly reduced from1 to3weeks, and the expression level ofmiR-
542-3p was the lowest at 3 weeks after induction (Figure 4b).
Then, we detected the expression of specific markers for
osteoblasts (ALP, RUNX2, and OCN) by qRT-PCR in MSCs transfected
with control miRNA, miR-542-3p, miR-542-3p inhibitor, or miR-542-
3pmutant. Comparedwith the control group, miR-542-3p significantly
increased the expression of osteoblast specific markers (p < 0.05)
(Figure 4c), whereas miR-542-3p inhibitor allowed these osteoblast
specific markers sharply decreased (p < 0.05) (Figure 4d). Moreover,
this promotion was eliminated in miR-542-3p mutant transfected
MSCs (Figure 4e).
2.4 | MiR-542-3p promotes bone formation in vivo
In order to investigate the function of miR-542-3p in vivo, we used
ovariectomy (OVX) rats to simulate postmenopausal status. Rats
undergoing Sham surgery or OVX were given miR-542-3p inhibitor by
FIGURE 1 OVX surgery leads to dramatically decreased bone loss in rats. Histological sections of femur in rats of the sham and OVX
groups. Sham: sham control group; OVX: the ovariectomized rats group; Scale bar, 100 μm. All sections were stained with HE
TABLE 2 Significantly regulated mRNA in the MSCs from
ovariectomized rats
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FIGURE 2 Expression of SFRP1 and miR-542-3p is significantly regulated in ovariectomized rats. (a–c) Expressions of SFRP1 protein (a),
sFRP1 mRNA (b), and miR-542-3p (c) in MSCs from OVX rats. *p < 0.05 compared with Sham rats. (D) Correlation analysis of miR-542-3p and
sFRP1 expressions in postmenopausal women with osteoporosis. SFRP1, secreted frizzled-related protein 1. We have drawn the correlation
formula: y = −0.5719x + 1.099 (x: expression level of sFRP1, y: expression level of miR-542-3p) (n = 23). All data were presented as
mean ± S.E.M. from three independent experiments. *p < 0.05
FIGURE 3 MiR-542-3p directly targets sFRP1. (a) Schematic diagram of miR-542-3p target site in the 3′ UTR of sFRP1 mRNA are shown
in complementary pairing. (b) The luciferase reporter carrying pGL3-sFRP1-3′UTR-WT or pGL3-sFRP1-3′UTR-Mut was co-transfected with
the miR-542-3p mimic or the control in HEK293T cells for 48 hr, and luciferase activity assay was performed. Firefly luciferase values
normalized for Renilla luciferase were presented. (c) HEK293T cells were transfected with miR-542-3p mimic, or the respective control for
48 hr. Western blot was used to detect the protein level of SFRP1. The data were from three independent experiments (n = 3). Data are
shown as means ± SD. *p < 0.05 versus control
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single tail vein injection. Phosphate buffer solution (PBS) or miR-542-
3p inhibitor mutant (mut) was used as a control. ByWestern blot, miR-
542-3p inhibitor-treated rats showed a higher expression level of
SFRP1 protein compared with PBS or miR-542-3p inhibitor mutant-
treated Sham rats or OVX rats (Figure 5a).
Then a significant decrease in BMDwas also detected. The results
showed that miR-542-3p inhibitor treated rats exhibited a significant
decrease in femur BMD compared to rats treated with miR-542-3p
inhibitor mutant or PBS. OVX rats treated with miR-542-3p inhibitor,
miR-542-3p inhibitor mutant or PBS also presented reduced femur
BMD, whereas miR-542-3p inhibitor treated rats showed minimal
BMD (Figure 5b).
Micro-CT was used to quantify the bone volume/tissue volume
ratio (BV/TV). This assay revealed that in Sham rats, a significant
decrease in BV/TV was detected in miR-542-3p inhibitor-treated rats
compared to rats treated with PBS or miR-542-3p inhibitor mutant
(p < 0.05) (Figure 5c). OVX rats treated with PBS or miR-542-3p
inhibitor mutant also exhibited a significant decrease in BV/TV, while
the lowest in the miR-542-3p inhibitor treated OVX rats (Figure 5c).
Compared with healthy controls, the femur bone mineral density
of OVX rats significantly decreased. Next, we measured several
parameters of femurs bone formation by histological analysis,
including the bone formation rate on each bone surface (BFR/BS)
and the osteoblast surface on each bone surface (Ob.S/BS). For BFR/
BS and Ob.S/BS, statistically significant reductions were detected
between the PBS or miR-542-3p inhibitor mutant and miR-542-3p
inhibitor-treated OVX rats or Sham rats (p < 0.05) (Figure 5d).
Furthermore, a statistically significant increase in BFR/BS and Ob.S/
BS was detected in OVX rats, compared to the sham group (p < 0.05)
(Figure 5d). The bone resorption parameters of rat femur were also
measured by histological analysis, including the osteoclast surface on
each bone surface (Oc.S/BS) and the number of osteoclasts per bone
perimeter (N.Oc/B.Pm). There was no statistically significant differ-
ence between PBS or miR-542-3p inhibitor mutant and miR-542-3p
inhibitor-treated OVX rats or control rats, indicating that osteoclast
bone resorption was not affected (Figure 5e). However, OVX rats
showed a statistically significant increase in Oc.S/BS and N.Oc/B.Pm
compared to control rats in all constructs (p < 0.05).
3 | DISCUSSION
Osteoporosis is a metabolic disorder characterized by osteoblast
formation and osteoclast resorption imbalance, leading to skeletal
fragility and fracture susceptibility. Ovarian hormone deficiency is a
major risk factor for postmenopausal women with osteoporosis. It is
well known that the OVX rats are the best animal model for the
research of postmenopausal osteoporosis in women (Hartke, 1999). In
the present study, we indicate that miR-542-3p is a novel miRNA that
could ameliorate ovariectomy-induced osteoporosis in rats by directly
targeting sFRP1.
There is a growing evidence that miRNAs play key roles in both
normal biological processes and the pathogenesis of human diseases
through post-transcriptional regulation of gene expression (Lamouille,
Subramanyam, Blelloch, &Derynck, 2013). Several decades ofmiRNAs
are considered necessary for bone formation (Lian et al., 2012). In this
study, we found a higher level of sFRP1 in MSCs from OVX rats and a
lower level of miR-542-3p in serum of OVX rats compared with Sham
rats. Additionally, a correlation analysis further confirmed that
FIGURE 4 MiR-542-3p is essential in MSC differentiation. (a) Expression of sFRP1 during osteoblast induction from rats MSCs (n = 3). Data
were normalized to β-actin mRNA at each time point. Expression of sFRP1 at 1 week was normalized to 1. (b) Expression of miR-542-3p
during osteoblast induction from rats MSCs (n = 3). Data were normalized to U6 RNA at each time point. Expression of miR-542-3p at 1 week
was normalized to 1. (c–e) MSCs cells were transfected with miR-542-3p mimic (c), miR-542-3p inhibitor (d), miR-542-3p mutant (e), or their
separate negative control. Expression of specific markers for osteoblasts (ALP, RUNX2 and OCN) was measured by qRT-PCR (n = 3). β-actin
was used as the internal control. The data were from three independent experiments (n = 3). *p < 0.05
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miR-542-3p and sFRP1 were negatively correlated in postmenopausal
osteoporotic patients. These results indicated that miR-542-3p may
play a vital role in osteogenic differentiation of MSCs.
Previous studies have shown that miR-542-3p is a tumor
suppressor that is abnormally down-regulated in several human
cancers. MiR-542-3p reduced cell viability, proliferation, tumor
angiogenesis, invasion and metastasis, and induced apoptosis by
targeting mRNAs, such as Survivin, FZD7, PIM1, cortactin, angiopoie-
tin-2, etc (Althoff et al., 2015; He et al., 2014; Long et al., 2016; Rang,
Yang,Wang, & Cui, 2016;Wu et al., 2017). However, miR-542-3pmay
function as an oncogene by targeting VANGL2 during osteosarcoma
pathogenesis (Li, Liu, Pei, Wang, & Lv, 2015). Recently, Farre et al
reported that elevated miR-542-3p/5p may lead to muscle atrophy in
ICU patients through promoting mitochondrial dysfunction and
activation of SMAD2/3 phosphorylation (Farre Garros et al., 2017).
However, the role of miR-542-3p in osteoporosis is unknown.
Here, we found that miR-542-3p regulates the osteogenesis
differentiation of rat MSCs by directly targeting sFRP1. SFRP1 is an
antagonist ofWnt signaling, which is an important pathway tomaintain
bone homeostasis. It has been reported that overexpression of SFRP1
in human osteoblasts accelerates the rate of osteoblast and osteocyte
mortality. The lack of SFRP1 in mice leads to reduced osteoblast and
osteocyte apoptosis (Bodine et al., 2005). Adult mice deficient in
SFRP1 showed resistance to age-related bone loss and improved
fracture repair by promoting early bone union (Bodine et al., 2004;
Gaur et al., 2009). In addition to osteoblast formation, SFRP1 can
directly bind to RANKL and inhibit osteoclast formation (Hausler et al.,
2004). Moreover, a small molecule inhibitor (diarylsulfone sulfon-
amide) that can bind and inhibit SFRP1was shown to stimulateWnt/β-
catenin signaling to increase bone formation (Bodine et al., 2009). All
these confirmed the importance of SFRP1 for bone formation, and
suggested that inhibition of SFRP1 may be a potential therapeutic
target for increasing bone formation.
Several evidences strongly suggest that SFRP1 is a functional
target of miR-542-3p and mediates its regulatory role in osteoblast
formation. First, SFRP1 may be a possible target with 9 nt consistent
matching site complementary to miR-542-3p in the 3′UTR of sFRP1.
Second, luciferase reporter assay showed that overexpression of
FIGURE 5 MiR-542-3p inhibitor-treated rats showed decreased bone mass and reduced osteoblast activity. (a–e) Wild-type rats were
ovariectomized or sham surgery. After 4 weeks, rats were injected with PBS, miR-542-3p inhibitor, or miR-542-3p inhibitor mutant, and
bones were harvested at 6 weeks after the first injection. (a) Expression of SFRP1 protein was analyzed by western blot. (b) Bone mineral
density (BMD) of femurs was measured. (c) Structure parameter bone volume per tissue volume ratio (BV/TV) was measured by micro-CT. (d)
Bone formation rate over bone surface area (BFR/BS) and osteoblast surface area over bone surface area (Ob.S/BS) were measured by
histomorphometric analysis. (E) Osteoclast surface area over bone surface area (Oc.S/BS) and the number of osteoclasts per bone perimeter
(N.Oc/B.Pm) were measured by histomorphometric analysis. *p < 0.05. Table 1 Bone mineral density of the femur
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miR-542-3p inhibited the activity of pGL3-sFRP1-3′UTR-WT,
whereas pGL3-sFRP1-3′UTR-Mut eliminated this inhibitory effect.
Third, the level of SFRP1 protein was decreased after overexpression
of miR-542-3p. Finally, during the process ofMSCs differentiation, the
SFRP1 protein showed a higher increase in OVX rats with a lower miR-
542-3p expression.
Then we observed the in vitro effect of miR-542-3p on osteoblast
differentiation using rat MSCs. MiR-542-3p enhanced the expression
of osteoblast specific markers. And we further investigated the in vivo
effects of miR-542-3p on ovariectomy-induced osteoporosis in rats.
Inhibition of miR-542-3p promoted SFRP1 protein expression,
decreased bone mass and bone formation, aggravated bone loss in
OVX rats. Whereas expression of miR-542-3p mutant did not inhibit
SFRP1 protein expression, bone mass and bone formation in OVX rats.
These data suggested that miR-542-3p influenced bone mass by
regulating bone formation in vivo, primarily through its effect on
SFRP1.
In conclusion, this study provides evidence that miR-542-3p in rat
MSCs regulate osteoblast formation by targeting sFRP1. Furthermore,
reduction of miR-542-3p expression in OVX rats results in attenuated
osteoblast formation and contributes to osteoporosis. Together, our
study has revealed that miR-542-3p plays an important role in the
pathogenesis of postmenopausal osteoporosis and contributes to the
development of a new therapeutic approach for osteoporosis.
4 | MATERIALS AND METHODS
This study was approved by the Medical Ethical Committee of
Kunming Medical University (Yunan, China). The written informed
consents were obtained from all the participants enrolled in the study.
And personal information on demographic factors was collected by
structured questionnaire. All experiment methods were performed in
accordance with the relevant guidelines and regulations.
4.1 | Animal studies
All procedures were approved by the Animal Care and Use Committee
of Kunming Medical University. Healthy specific-pathogen-free (SPF)
female Sprague–Dawley (SD) rats were purchased from the Vital River.
All rats were preserved under standard housing laboratory conditions.
After 1 week of adaptation to the diet and the new environment, the
rats were randomly divided into two groups: OVX group and sham-
operated group (Sham). All surgeries were performed by one person
under anesthesia by ketamine 10% (100mg/kg, Alfasan, Netherlands)
and xylazine 2% (10mg/kg, Alfasan, Netherlands). 45 or 90 days post-
surgery, rats were weighed again and anesthetized with ketamine and
xylazine solution intraperitoneally and sacrificed by using thiopental
(100mg/kg) at the end of the experiment. The left femora and the L2-5
vertebraewith the skin andmuscle removedwere kept in physiological
saline and stored at −20°C for detection of BMD and for biomechanics
procedures. For protein and RNA analysis, the right femora, L1
vertebrae and tibiae were frozen in liquid nitrogen, and stored at
−80°C until use.
4.2 | Reagents and antibodies
SFRP1 and β-actin antibody were purchased from Abcam (Cambridge,
UK). MiR-542-3p mimic/inhibitor/inhibitor mutant and non-specific
control were obtained from RiboBio (Gua ngzhou, China). Lipofect-
amine 2000 was purchased from Invitrogen.
4.3 | Cell culture
HEK293T cells were obtained from American Type Culture Collection.
Primary bone marrow-derived mesenchymal stem cells (MSCs) were
isolated from 4-month old SD female rat. The cell lines were cultured
with DMEM containing 10% FBS, supplemented with 100 μg/ml
streptomycin and 100U/ml penicillin, at 37 °C in a humidified
atmosphere of 5% CO2.
4.4 | RNA isolation and quantitative real-time PCR
Total RNA was isolated with TRIzol reagent (Invitrogen Life Technologies,
Carlsbad CA) according to the manufacturer's protocol. cDNA was
synthesized with a Reverse Transcription Kit (TOYOBO, Tokyo, Japan)
according to the manufacturer's instruction. Quantitative real-time PCR
(qRT-PCR) was carried out using ABI 7500. The following primers were
used: GAPDH, forward: 5′-TGGCCTTCCGTGTTCCTAC-3′, reverse: 5′-
GAGTTGCTGTTGAAGTCGCA-3′; secreted frizzled related protein 1
(SFRP1), forward: 5′-TACTGGCCCGAGATGCTCAA-3′, reverse: 5′-
GAGGCTTCCGTGGTATTGGG-3′; alkaline phosphatase (ALP), forward:
5′-TCAGGGCAATGAGGTCACAT-3′, reverse: 5′-CCTCTGGTGGCAT
CTCGTTA-3′ runt related transcription factor 2 (RUNX2), forward: 5′-
GACTGTGGTTACCGTCATGGC-3′, reverse: 5′-ACTTGGTTTTTCATAA-
CAGCGGA-3′ osteocalcin (OCN), forward: 5′-CCCTGAGTCTGA-
CAAAGCCT-3′, reverse: 5′-GCGGTCTTCAAGCCATACTG-3′.
4.5 | RNA-seq library preparation and sequencing
Total RNA was extracted by the same method used for qRT–PCR. The
RNA quality was checked by a 2,100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA) and only high quality samples were used to
construct the sequencing library. Then RNA-seq libraries were
sequenced using the Illumina HiSeq 2,000 Sequencing System.
Read counts mapped to each gene were calculated by HTseq
(http://www-huber.embl.de) with the default model. Fragments per
kilobase of exon model per million fragments mapped values were
calculated using Cufflinks (version 2.1.1, http://cufflinks.cbcb.umd.
edu). Differential expression was analysed with R (v2.14.0,
http://www.R-project.org) and Bioconductor (release 2.10) with the
R package DESeq (v1.6.0). miRNA targets were predicted by
miRWalk2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/
index.html).
4.6 | Western blot
Cells were lysed in RIPA buffer plus protease inhibitors (Roche,
Indianapolis, IN). Equal amount of proteins were loaded, and separated
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on 10% SDS–PAGE and then transferred to a nitrocellulose (NC)
membrane (BD), blocked by incubation with 5% fat-free milk in TBST
buffer (150mM NaCl, 50mM Tris-HCl, 0.5% Tween20, pH 7.6) at
room temperature for 1 hr. The membranes were incubated with
primary antibodies at 4 °C overnight, and then were incubated with
horseradish peroxide-conjugated secondary antibodies at room
temperature for 1 hr. The blots were developed with ECL reagent
(Thermo Fisher Scientific, Pierce, Rockford, IL).
4.7 | Luciferase assays
The 3′UTR of SFPR1 was amplified using the following primers:
forward: 5′-CTGGTTGATTCACTCAAGAGTTC-3′, reverse: 5′-
TATCTGCTGGCAACAGGTCAGAAC-3′. The PCR product was puri-
fied and then inserted into pGL3within Xho I andNot I restriction sites.
The QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA) was used to introduce mutations into the seed region of pGL3-
sFRP1-3′UTR-WT. HEK293T cells were co-transfected with 0.5 µg of
the reporter vector (pGL3-sFRP1-3′UTR-WT or pGL3-sFRP1-3′UTR-
Mut) and 1 µg of miR-542-3p mimic or non-specific control. Forty-
eight hours after transfection, cells were harvested and luciferase
activity was detected using a dual-luciferase reporter assay system
(Promega, Madison, WI).
4.8 | Bone mineral density measurement
Bone mineral density (BMD) of the femur at the end of the experiment
by Lunar Prodigy Advance (GE Healthcare, Pittsburgh, PA) using
appropriate software specifically for rats (Pastoureau, Chomel, &
Bonnet, 1995). Results are given in g/cm2.
4.9 | Bone histomorphometric analysis
For histological analyses, the femurs were fixed in 70% ethanol,
embedded in methyl methacrylate, and serial sectioned into 5-µm by a
microtome. The parameters obtained for the bone formation were
BFR/BS and Ob.S/BS. The parameters measured for bone resorption
were Oc.S/BS and N.Oc/B.Pm.
After euthanasia, the femurs were resected and fixed in 10%
formalin for 48 hours, decalcified in 10% ethylenediamine tetraacetic
acid (EDTA) (pH 7.0) for 14 days and embedded in paraffin.
Hematoxylin and eosin (HE) staining was performed according to
the previous study (Huang, Yang, Hsieh, & Liu, 2002).
4.10 | Statistical analysis
Data are presented as mean ± standard deviation (SD). The statistical
analysis was performed using Student t test or one-way ANOVA. All
experiments were repeated at least three times, and representative
experiments are shown. Differences were considered significant at
p < 0.05.
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